domingo, 3 de marzo de 2019

Ultomiris: Can drug innovation be too expensive? - STAT

Ultomiris: Can drug innovation be too expensive? - STAT

First Opinion

Ultomiris: Can drug innovation be too expensive?

By ALEXANDER URRY


ADOBE
Alexion's blockbuster drug Soliris will soon go off patent. It's new drug, Ultomiris, does the same task. Should this innovation get full patent protection?

No hay comentarios: